Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Xiaoyong Liu,Xiao-Ming Ren,Miao Hua,Fang Liu,Xiaoping Ren,Cong Sui,Qing Li,Fen Luo,Zhi‐Yong Jiang,Ziqiao Xia,Jingxia Chen,Bing Yang
DOI: https://doi.org/10.1111/cbdd.14425
2023-01-01
Chemical Biology & Drug Design
Abstract:The pneumonia outbreak caused by Severe Acute Respiratory Syndrome 2 (SARS‐CoV‐2) infection poses a serious threat to people worldwide. Although vaccines have been developed, antiviral drugs are still needed to combat SARS‐CoV‐2 infection due to the high mutability of the virus. SARS‐CoV‐2 main protein (M pro ) is a special cysteine protease that is a key enzyme for SARS‐CoV‐2 replication. It is encoded by peptides and is responsible for processing peptides into functional proteins, making it an important drug target. The paper reviews the structure and peptide‐like inhibitors of SARS‐CoV‐2 M pro , also the binding mode and structure–activity relationship between the inhibitors and M pro are introduced in detail. It is hoped that this review can provide ideas and help for the development of anti‐coronavirus drugs such as COVID‐19, and help to develop broad‐spectrum antiviral drug for the treatment of coronavirus diseases as soon as possible.
What problem does this paper attempt to address?